Summary: Capital One Financial initiated coverage on Heron Therapeutics with an overweight rating and a $6.00 price target. Other research analysts have also issued positive ratings for the company. Heron Therapeutics recently reported better-than-expected quarterly earnings. Institutional investors have shown interest in the company.
Full articleSummary: Capital One initiated coverage of Heron Therapeutics (NasdaqCM:HRTX) with an Overweight recommendation and a projected 175.68% upside in the stock price. Multiple institutional investors hold significant amounts of shares in Heron Therapeutics.
Full article